Insider Selling: Rhythm Pharmaceuticals Inc (RYTM) CEO Sells 3,934 Shares of Stock

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) CEO Keith Michael Gottesdiener sold 3,934 shares of the company’s stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $30.00, for a total value of $118,020.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Keith Michael Gottesdiener also recently made the following trade(s):

  • On Wednesday, January 23rd, Keith Michael Gottesdiener sold 15,779 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.05, for a total value of $474,158.95.
  • On Friday, January 18th, Keith Michael Gottesdiener sold 10,115 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.01, for a total value of $303,551.15.
  • On Wednesday, January 16th, Keith Michael Gottesdiener sold 662 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $19,860.00.

Shares of RYTM stock traded up $0.33 on Friday, hitting $30.04. The company had a trading volume of 85,269 shares, compared to its average volume of 87,562. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -10.61 and a beta of 1.41. Rhythm Pharmaceuticals Inc has a twelve month low of $16.80 and a twelve month high of $37.23.

A number of equities analysts have issued reports on RYTM shares. Needham & Company LLC set a $42.00 target price on Rhythm Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 14th. Zacks Investment Research cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 15th. BidaskClub raised Rhythm Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $36.00 price target on shares of Rhythm Pharmaceuticals in a research note on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Rhythm Pharmaceuticals has an average rating of “Buy” and a consensus price target of $38.25.

Several hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC increased its stake in shares of Rhythm Pharmaceuticals by 33.1% in the third quarter. Janus Henderson Group PLC now owns 3,050,838 shares of the company’s stock valued at $88,993,000 after buying an additional 759,053 shares during the period. BlackRock Inc. increased its stake in shares of Rhythm Pharmaceuticals by 36.2% in the fourth quarter. BlackRock Inc. now owns 1,554,706 shares of the company’s stock valued at $41,790,000 after buying an additional 413,203 shares during the period. Vanguard Group Inc. increased its stake in shares of Rhythm Pharmaceuticals by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,048,186 shares of the company’s stock valued at $30,575,000 after buying an additional 115,177 shares during the period. Vanguard Group Inc increased its stake in shares of Rhythm Pharmaceuticals by 12.3% in the third quarter. Vanguard Group Inc now owns 1,048,186 shares of the company’s stock valued at $30,575,000 after buying an additional 115,177 shares during the period. Finally, Federated Investors Inc. PA increased its stake in shares of Rhythm Pharmaceuticals by 216.2% in the third quarter. Federated Investors Inc. PA now owns 790,421 shares of the company’s stock valued at $23,057,000 after buying an additional 540,421 shares during the period. 90.56% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/2019/02/15/insider-selling-rhythm-pharmaceuticals-inc-rytm-ceo-sells-3934-shares-of-stock.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Featured Story: What is the LIBOR?

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.